Your AI-Trained Oncology Knowledge Connection!
Dysregulation of the JAK pathway plays a role in the development of numerous tumor types; it is particularly central to the pathophysiology of myelofibrosis and has long been recognized as a potentially valuable therapeutic target in that malignancy.
Right-to-try legislation, which allows dying patients to take investigational medications without approval from the FDA.
There is a critically important subject associated with the clinical trial experience that has had inadequate discussion within the medical literature, regarding the role of the patient beyond agreeing to serve as a research subject.
The effort to improve outcomes of disadvantaged patients involves every aspect of lung cancer care.
Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.
Given that few options are available for intrahepatic cholangiocarcinoma, investigators are excited about a phase III trial of the multikinase inhibitor derazantinib as a second-line treatment for patients with inoperable or advanced disease.
